Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP160-Complex in Advanced Solid Tumors
NCT05653661Phase 1Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Jul 2024
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of danburstotug in solid tumor (advanced stage), metastatic solid tumors and melanoma, sponsored by Mayo Clinic. Primary endpoint: Maximally Tolerated Dose at 28 days. Planned start Jul 2024; status: withdrawn.
02
Drugs
danburstotug
03
Conditions
solid tumor (advanced stage)metastatic solid tumorsmelanoma
Beyond the preview
Go deeper on NCT05653661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05653661.